2.35
+9.81%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About INVO Fertility
From its filings with the US Securities and Exchange Commission
INVO Fertility is based in Sarasota, Florida and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker IVF. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $6.8m and a net loss of $23.3m. At that date it held total assets of $20.2m and shareholders' equity of $7.2m.
Form 10-K certain material events and developments that have taken place through the date of filing of this Form 10-K with the SEC.
August 10, 2023, we consummated the first acquisition of an existing fertility clinic, the Wisconsin Fertility Institute (“WFI”).
Group LLC (“Maxim”) acted as our financial advisor in connection with the inducement transaction.
The Pre-Funded Warrants were immediately exercisable at $0.0005 per share until exercised in full.
Beginnings P.C. acquisition, paying certain outstanding debt obligations, and providing additional working capital.
Sheet”) to settle all disputes between the parties pursuant to the terms set forth in the Term Sheet (the “Terms”).
Shares received in such exchange equal to the principal amount so exchanged plus accrued and unpaid interest thereon (an “AIR Exchange”).
As a result, the Second Amended and Restated Debenture was paid in full and fully extinguished.
Alpha V LP (the “Lender”) under which the Lender advanced a gross amount of $1,500,000 to us.
We received stockholder approval for the issuance of shares of common stock upon exercise of such new warrants on July 23, 2025.
Quoted from its 10-K, filed 2 Jun 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 11 Nov 2008
- Employees
- 15
- Website
- invobioscience.com ↗
- Head office
- 5582 BROADCAST COURT, SARASOTA, FL, 34240
- Incorporated in
- NV
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Steven ShumChief Executive Officer, Director, since 2017$260,000
- Mr. Andrea GorenChief Financial Officer$215,000
- Mr. Daniel TeperDirector, since 2024$137,548
- Mr. Trent DavisIndependent Director$42,500
- Ms. Rebecca MessinaIndependent Director$42,500
- Ms. Barbara RyanIndependent Director$52,500
- Mr. Matthew SzotIndependent Director$47,500
- Mr. Robert BlumInvestor Relations, since 2019
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company operates three INVO Centers in North America to commercialize its technology.
- The flagship product INVOcell allows fertilization to take place in vivo within the woman’s body.
- The intravaginal culture technique provides patients a more connected and intimate experience compared to in vitro fertilization.
Weaknesses
- The company currently employs only 15 full-time employees.
- The business is headquartered in Lakewood Ranch, Florida, limiting its geographic presence to the US.
- The company operates solely in the Health Care Equipment & Supplies industry without diversification.
Opportunities
- The firm is focused on expanding the assisted reproductive technology marketplace globally.
- The commercialization strategy includes the acquisition of existing IVF clinics to grow its network.
- The company aims to make fertility care accessible and inclusive to people around the world.
Threats
- The company faces competition from the established in vitro fertilization treatment market.
- The reliance on a single medical device product line creates concentration risk.
- The small workforce of 15 employees may limit operational scalability and execution capacity.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.